启迪药业(000590) - 2014 Q1 - 季度财报

Financial Performance - Revenue for the first quarter was ¥55,847,132.12, a decrease of 42.11% compared to ¥96,477,942.08 in the same period last year[8] - Net profit attributable to shareholders was ¥2,977,699.60, down 81.09% from ¥15,748,180.28 year-on-year[8] - Basic earnings per share decreased to ¥0.0133, down 81.13% from ¥0.0705 in the same period last year[8] - The weighted average return on equity was 1.1%, down from 3.24% in the same period last year[8] - Main business income decreased by 43.15% to ¥67,248,864.88 from ¥118,300,801.74 due to reduced sales of goods and services[18] Cash Flow - The net cash flow from operating activities was -¥4,790,333.32, a decline of 119.95% compared to ¥24,010,650.64 in the previous year[8] - Cash flow from operating activities showed a net outflow of ¥4,790,333.32, a decline of 119.95% compared to the previous period[18] - Cash received from investment recovery surged by 12,019.77% to ¥60,000,000.00, primarily from the recovery of financial products[19] - Investment activities generated a net cash flow of ¥5,725,589.26, an increase of 261.41% compared to the previous period[19] - Cash received from investment income reached ¥655,166.66, marking a 100% increase as it was the first time this income was recorded[19] - The company acquired bank loans amounting to ¥500,000.00, representing a 100% increase from the previous period[19] Asset Management - Total assets at the end of the reporting period were ¥519,376,874.43, a decrease of 6.01% from ¥552,561,938.86 at the end of the previous year[8] - The company experienced a 63.64% reduction in asset impairment losses, primarily due to a decrease in bad debt provisions[17] - The company holds 150,000 shares of Guotour United, valued at ¥754,500.00, with an initial investment cost of ¥174,747.85[20] Shareholder Information - The total number of shareholders at the end of the reporting period was 15,523[11] - No significant commitments from shareholders were reported during the period[20] Business Operations - The company reported a significant decrease in main business income due to adjustments in the sales model of traditional Chinese medicine products and the suspension of Western medicine infusion products[17] - Operating income from non-recurring items increased significantly to ¥1,689,844.92, up 4378.78% from ¥37,730.00 in the previous year[17] - The company did not report any derivative investments during the period[21] - The company engaged in communication with ordinary investors regarding its production and operational status[21]